Bright Minds Biosciences Inc

NAS:DRUG (USA)   Ordinary Shares
$ 1.19 0 (0%) 10:08 PM EST
At Loss
P/B:
1.23
Enterprise V:
$ 478.00K
Volume:
15.93K
Avg Vol (2M):
24.26K
Also Trade In:
Volume:
15.93K
At Loss
Avg Vol (2M):
24.26K

Business Description

Bright Minds Biosciences Inc
NAICS : 325412 SIC : 3741
ISIN : CA10919W4056

Share Class Description:

DRUG: Ordinary Shares
Description
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Name Current Vs Industry Vs History
Cash-To-Debt 122.95
Equity-to-Asset 0.88
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 30.26
9-Day RSI 36.24
14-Day RSI 37.18
6-1 Month Momentum % -16.67
12-1 Month Momentum % -37.38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.01
Quick Ratio 8.01
Cash Ratio 7.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -43.3
Shareholder Yield % -11.54
Name Current Vs Industry Vs History
ROE % -83.44
ROA % -76.78
ROIC % -4390.04
ROC (Joel Greenblatt) % -8022.46
ROCE % -84.05

Financials

DRUG's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:DRUG

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Bright Minds Biosciences Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.32
Beta 1.12
Volatility % 111.04
14-Day RSI 37.18
14-Day ATR ($) 0.12336
20-Day SMA ($) 1.236625
12-1 Month Momentum % -37.38
52-Week Range ($) 1.09 - 6.44
Shares Outstanding (Mil) 4.46

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Bright Minds Biosciences Inc Filings

Filing Date Document Date Form
No Filing Data

Bright Minds Biosciences Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Bright Minds Biosciences Inc Frequently Asked Questions

What is Bright Minds Biosciences Inc(DRUG)'s stock price today?
The current price of DRUG is $1.19. The 52 week high of DRUG is $6.44 and 52 week low is $1.09.
When is next earnings date of Bright Minds Biosciences Inc(DRUG)?
The next earnings date of Bright Minds Biosciences Inc(DRUG) is .
Does Bright Minds Biosciences Inc(DRUG) pay dividends? If so, how much?
Bright Minds Biosciences Inc(DRUG) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1